Antibiotic tested as new weapon against fatty liver
NCT ID NCT07381257
Summary
This early-stage study is testing whether a gut-targeted antibiotic called rifaximin-α can reduce fat buildup in the liver for people with metabolic dysfunction-associated steatotic liver disease (MASLD). Sixty participants will be assigned to take the drug or not for 24 weeks while also following diet and exercise advice. The main goal is to see if the treatment safely lowers liver fat content, measured by MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng Hospital, Naval Medical University, shanghai, China
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.